Fig. 4: Survival analysis of the BCLs and TCLs with respect to somatic mutation in the influential genes.
From: Identification of novel genetic mutations for the treatment prognostication of canine lymphoma
PFS or OS of the patients following CHOP therapy or treatment via lomustine- or rabacfosadine-containing regimens are compared with respect to mutation in A PIK3CD, B NOTCH2, C KMT2C, and D CREBBP for TCLs, and E FBXW7, F TRAF3, G KMT2D, and H CCND1 for BCLs.
